

## **Ortho RTi Announces Compelling Data from Ortho-R Pilot Study in Rotator Cuff Repair**

**Kirkland, QC, April 2, 2018** - Ortho Regenerative Technologies Inc. (CSE: ORTH.CN) (“Ortho RTi” or the “Corporation”), an emerging Orthopaedic and Sports Medicine Technology company, today announced positive preliminary MR imaging outcomes data from a study examining its Ortho-R technology in the biologic repair of rotator cuff injuries.

Conducted by researchers from Montreal’s prestigious École Polytechnique, the pilot dose escalation study used MR imaging outcomes, read by two blinded experts at 3 intervals, to compare the results of Ortho-R versus standard of care in a non-clinical rotator cuff injury model in sheep. In this study, treatment with Ortho-R was shown to significantly improve healing, as measured by gap reduction between the tendon and bone, versus standard of care, with the highest Ortho-R dose having the greatest effect. Detailed results from the study will be submitted to a future medical conference and for publication.

“We are very encouraged by this data, as Ortho-R demonstrated an ability to induce healing in as little as three months,” said Ortho RTi’s Executive Chairman and CEO, Dr. Brent Norton. “With a small study size, getting meaningful data is challenging, yet the relative gap reduction induced by Ortho-R was statistically significant ( $p=0.01$ ). With more than 500,000 rotator cuff surgeries being performed in the United States each year, and with that number continuing to grow, we are looking forward to taking this technology into the clinic as soon as possible. To that end, we are beginning to make preparations to submit an Investigational New Drug Application to the FDA for this, our lead indication. As always, we look forward to updating our stakeholders as we progress.”

### **About Rotator Cuff Injury**

The rotator cuff is the name given to the collection of four tendons that stabilize the shoulder joint. The tendons around the joint can suffer tears as a result of injury to the tendon or as a result of degeneration over time. Repetitive overhead activity, including weight lifting is often associated with cuff tears. Symptoms include a dull, aching pain, and patients often suffer secondary symptoms including a lack of sleep and weakness in the arms resulting from a lack of exercise. If conservative therapy (for example, painkillers and physical rehabilitation) is not successful, surgery will often be performed. The principle aim of surgical intervention is to reattach the torn tendon to the bone. The standard of care involves the use of suture anchors placed into the bone and the tendon being then held in place with sutures.

### **About Ortho Regenerative Technologies Inc.**

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at [www.orthorti.com](http://www.orthorti.com).

### **Forward-Looking Statements**

*This news release may contain certain forward-looking statements regarding the Corporation’s expectations for future events. Such expectations are based on certain assumptions that are founded on*

*currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.*

For further Information, please contact:

Stephen Kilmer  
Investor & Media Relations  
647.872.4849  
kilmer@orthorti.com